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Summary
Approximately 50% of patients with colorectal cancer (CRC) will developduring their lifespan. Majority of colorectal 
liver metastases (CLM) patients will be unresectable at the time of diagnosis due to extensive intrahepatic and/or extrahe-
patic disease. R0 liver resection is still the only available treatment that allows long-term survival. In last two decades, the 
5-year overall survival (OS) after curative liver resection of CLM has increased up to 58%. These improved outcomes are 
mainly due to multidisciplinary treatment of these patients. The definition of resectability has changed, so nowdays, the 
goal is the completion of R0 resection and normal liver function maintenance. Conversional (neoadjuvant) chemotherapy, 
portal vein embolization, two-stage hepatectomy, and tumour ablation are effective approaches to improve resectability for 
initially unresectable patients. The role of perioperative chemotherapy, for clearly resectable patients, still needs to be clari-
fied. It results in longer disease-free survival (DFS) and OS times, but it is not clear whether it is the neoadjuvant or the ad-
juvant component that provides the benefit.Disadvantages of neoadjuvant chemotherapy are either progression or complete 
remission during treatment, and their managment is challenging. According to available data the efficacy of adjuvant che-
motherapy after CLM resection is questionable. However, the ideal chemotherapy and its optimal sequencing in the course 
of treatment are uncertain.Equally, the influence of chemotherapy-associated toxicity on the outcome of liver resection 
needs to be further explored. There is debate over whether the primary tumour and metastases should be removed at the 
same time or in a staged manner. Targeted therapy with novel biological agents such as bevacizumab and cetuximab, in 
addition to traditional chemotherapy, has been shown to improve the survival of unresectable CLM patients. The majority 
of patients will develop recurrent disease in the liver within the first two years after surgery, despite any mode of treatment 
that they have received. Therefore, a repeat resection is recommended as the only chance to prolong DFS and OS. Conse-
quently, all of these issues demand an modern oncosurgical and multidisciplinary approach to the each individual with 
liver surgeon having a central role in treatment planning.
KEYWORDS:  colorectal cancer, liver metastases, multidisciplinary treatment, chemotherapy; R0 resection, 
portal vein embolization
KIRUR[KO LIJE^ENJE KOLOREKTALNIH METASTAZA U JETRI
Sa`etak
Oko 50% bolesnika s rakom debelog crijeva razviti }e metastaze u jetri tijekom svog `ivotnog vijeka. Na`alost, ve}ina 
bolesnika sa metastatskim kolorektalnim karicnomom }e biti inoperabilna u vrijeme postavljanja dijagnoze zbog opse`ne 
intrahepati~ke i / ili ekstrahepati~ke bolesti. R0 resekcija jetre je jo{ uvijek jedini dostupni oblik lije~enja koji omogu}uje 
dugoro~no pre`ivljenje. U posljednja dva desetlje}a, 5-godi{nje pre`ivljenje nakon kurativneresekcije jetre poraslo je na 58%. 
Ti pobolj{ani rezultati su uglavnom posljedica multidisciplinarnog lije~enja tih bolesnika, iako je optimalnog algoritam jo{ 
uvijek upitan. Definicija resektabilnosti se promijenila, pa se danas kao cilj lije~enja postavlja mogu}nost R0 resekcije uz 
normalno postoperativno odr`avanje jetrene funkcije. Neoadjuvantna kemoterapija, embolizacija poralne vene, hepatekto-
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mija u dva akta ilokalna ablacija su u~inkoviti pristupi u konverziji inicijalno inoperabilnih pacijenata u operabilne. Ulogu 
perioperativne kemoterapije, za evidentno operabilne bolesnike, jo{ treba razjasniti. Perioperativna kemoterapija rezultira 
duljim periodom bez bolesti i ukupnim pre`ivljenjem, ali nije jasno da li je neoadjuvanta ili adjuvantna komponenta ta koja 
pru`a korist. Potencijalni nedostaci neoadjuvantne kemoterapije su ili napredovanje ili potpuna remisija tijekom lije~enja, a 
lije~enje tih bolesnika je izazov. Prema sada{njim podacima iz literature, u~inkovitost adjuvantne kemoterapije nakon re-
sekcije metastatskog kolorektalnog karcinoma je upitna. Isto tako, idealni kemoterapijski protokol, sa ili bez biolo{kih agen-
sa, i njeno optimalno sekvenciranje u tijeku lije~enja je upitno. Isto tako, utjecaj, s kemoterapijom povezane toksi~nosti, na 
ishod kirur{kog lije~enja treba dodatno istra`iti. Jo{ uvijek se raspravlja o tome da li primarni tumor i metastaze treba uklo-
niti u isto vrijeme ili operacijama u dva akta. Za jasno inoperabilnog bolesnika, jo{ je uvijek upitno da li primarni tumor 
treba resecirati. Ciljana terapija s novim biolo{kim agensima, kao {to su bevacizumab i cetuksimab, uz tradicionalne kemo-
terapijske protokole, dokazano pobolj{ava pre`ivljenje kod definitivno inoperabilnih bolesnika. Ve}ina bolesnika s metasta-
tskim kolorektalnim karcinomom (55% -60%), }e se razviti intrahepatalni recidiv unutar prve dvije godine nakon kirur{kog 
zahvata, bez obzira na modalitet lije~enja. Stoga se ponovljene resekcije jetre preporu~uju kao jedina mogu}a opcijakoja 
mo`e produ`iti `ivot ovim bolesnicima. Prema tome, sva ova otvorena pitanja zahtijevaju suvremenionko-kirur{kipristup 
svakom pojedinom bolesniku, u sklopu multidisciplinarnog tima, s kirurgomu glavnoj ulozi kod planiranja lije~enja.
KLJU^NE RIJE^I:  kolorektalni karcinom, metastaze jetre, multidisciplinarno lije~enje, R0 resekcija, kemoterpija, 
embolizacija vene porte
patic disease. Initialy, about 10%-20% of patients 
with CLM are candidates for curative resection. 
However, modern oncosurgical strategies and 
multidisciplinary treatment including neoadju-
vant chemotherapy, preoperative portal vein em-
bolization (PVE) and two-stage hepatectomies, al-
lows another 16%-37% of CLM patients previously 
considered unresectable,to be downsized and eli-
gible for liver resection(10–12). Having in mind 
above information, in Croatia should be approxi-
mately 600-700 CLM patients resected annualy, 
but on the contrary, according to available data, in 
eight major Croatian hospitals only about 300 pa-
tients per year undergo resection for CLM(2). Sub-
stantially the question arises: where the other pa-
tients with CLM end up ? The one of the goals of 
this paper is to try to answer to the question above 
by emphasizing the need that patients with CLM 
should be treated in high volume centers where 
they can recieve high quality preoperative evalua-
tion, imaging and multidisciplinary treatment. 
Current data presented in this paper support a 
central role of liver surgeon in the planning of in-
dividualized treatment and by that offering such 
patients the best chance for prolonged survival 
which is R0 resection with curative intent.
PREOPERATIVE EVALUATION
Preoperative evaluation before resection of 
CLM are focused on: determining the diagnosis; 
INTRODUCTION
Colorectal cancer (CRC) is the third most 
common malignancy in the world, with an aver-
age of one million new cases and half a million 
deaths annually (1). Cancer of the colon and rec-
tum is the second most common malignancy in 
Croatia (after lung cancer in men and breast can-
cer in women) and the second most common cause 
of death after lung cancer (2). According to the 
Croatian State Cancer Registry, in 2011, in Croatia 
were 2820 CRC cases; 1172 women and 1648 men, 
which means 13% of all newly diagnosed cancers 
in women and 15% in men, respectively (2). Ap-
proximately 50% of patients with CRC will devel-
op liver metastases, whether synchronous or 
metachronous, during their lifespan (1,3). About 
15%-25% of CRC patients have synchronous liver 
metastases wich means presence of metastases at 
the time of diagnosis of the primary tumor or 
within 6 months of diagnosis (4,5). On the other 
hand, metachronous liver metastases will develop 
20%-25% of patients with colorectal cancer (6). 
Data from numerous retrospective and compara-
tive studies indicates that liver resection is still the 
only available treatment that allows long-term 
survival. In last two decades, the 5-year overall 
survival (OS) after curative liver resection of 
colorectal liver metastases (CLM) has increased to 
35%-58% (7–9). Unfortunately, majority of CLM 
patients will be unresectable at the time of diagno-
sis due to extensive intrahepatic and/or extrahe-
43
Libri Oncol., Vol. 41 (2013), No 1–3, 41 – 58
anatomically defining the lesion in the liver pa-
renchyma for surgical planning and accurate stag-
ing to rule out extrahepatic disease.
Clinical presentation
CLM are rarly symptomatic and usualy diag-
nosed with follow up cross-sectional imaging, 
such as computed tomography (CT) or magnetic 
resonance imaging (MRI). Approximatly 80% of 
metastases are detected in the first 3 years after 
diagnosis of the primary tumour, annual CT/MRI 
is recommended by the National Comprehensive 
Cancer Network 3-5 years after primary resection 
(13). Occasionally , patients present with symp-
toms such as pain, abdominal distention, and liver 
insuffi ciency. These patients usually have ad-
vanced CLM with significant hepatic tumor bur-
den and are less likely to be treated.
Preoperative imaging
Nowadays, ultrasound (US), helical CT, MRI 
and positron emission tomography/CT (PET/CT) 
are main options for imaging of CRC and CLM.
Ultrasonografy (US)
US is widely used, inexpensive and reliable 
test, but has been replaced by cross-sectional im-
aging mainly due to user dependence and lower 
sensitivity for small lesions. It can give informa-
tion regarding the size of the metastatic tumor and 
the extent of liver involvement. Besides, CD ultra-
sound can help defining the relation of the tumor 
to the vascular and biliar structures. Ultrasound 
may be used as a first line modality in the diag-
nostic of hepatic metastases during regular follow 
up after resection of the primary tumour. US, 
however, is most useful as intraoperative tool. 
Scaife et al (14) reported that intraoperative ultra-
sonografy (IOUS) identified additional hepatic tu-
mors in 27% of patients who underwent hepatic 
resection after state-of-the-art preoperative CT 
imaging. That study provides evidence that IOUS 
isstill important modality in assessment of hepatic 
malignancies in patients who receive surgical 
treatment.
Cross-sectional imaging ( CT, MRI and PET/CT)
So far, there is no gold standard of cross-sec-
tional technique for identifying liver metastases or 
anatomic structures and much of it depends on in-
stitutional preferences. Computed tomography 
(CT) still plays central role in selecting patients for 
hepatic resection. Multi–detector helical comput-
ed tomography (MD-CT) is fast, relatively inex-
pensive, and with the addition of intravenous 
contrast and thin slices provides an adequate view 
of metastases which appear hypovascular to the 
surrounding liver tissue. Disadventages of MD-
CTinclude radiation exposure, toxicity of contrast 
and inability to characterize lesions less than 1 cm 
in size (15).
Magnetic resonance imaging (MRI) has re-
cently been increasingly used as cross-sectional 
imaging modality to diagnose CLM. While the im-
ages can be of lower resolution than MDCT, they 
are capable to differentiate much better small liver 
lesions using the amount of water present. CLM 
appear hypointense to surrounding liver paren-
chyma on T1 images and hyperintense on T2 and 
diffusion weighted sequences. Compared with 
MDCT, MRI requires patient compliance because 
imaging lasts longer (although does not include 
radiation exposure), is relatively expensive with 
many contraindications (due to metallic implants) 
and typically only images the region of interest. A 
most important advantage of MRI over other im-
aging modalities is its ability to identify even small 
lesions, less than 1 cm in diameter (15). Such abil-
ity is useful in detecting smaller lesions in stea-
totic livers, especially after neoadjuvant treatment.
MRI is also more useful than MDCT in defining 
the relationship of the lesions to the hepatic vascu-
lature and the biliary tree with MR cholangiopan-
creatography (MRCP). Bipat at al. (16) in their 
meta-analysis concluded that MR imaging is pre-
ferred as the first-line modality for evaluating 
colorectal liver metastases, particularly in patients 
who have not previously undergone therapy; it 
provides anatomic details and has a high detec-
tion rate, even for lesions smaller than 10 mm.
Positron emission tomography (PET) relies 
on the propensity of hypermetabolic tissue to take 
up radioactive tagged glucose molecules. The 
most common tracer in PET scanning is fluoro-18-
deoxyglucose (FDG)-PET, a glucose analog, which 
can proceed down the glycolytic pathway, and ac-
cumulate within the glucose-avid cancer cells. 
Commonly, it is performed in combination with 
CT to allow better localization of hypermetabolic 
foci. PET is not particularly useful in imaging in-
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trahepatic tumors, because of the high physiologic 
metabolic activity of liver tissue. Main purpose is 
to help identify and characterize radiologically oc-
cult extra–hepatic disease in patients with e.g. 
 elevated CEA level and normal or nonspecific 
CT/MRI findings (17). A basic limitation of a PET 
scan is the reduced sensitivity in detecting sub-
centimeter lesions, mucinous lesions, and lesions 
that have been treated with neoadjuvant chemo-
therapy (18). In summary, multiple studies have 
compared the three modalities with regards to 
liver disease with most finding greatest sensitivity 
and specificity with MRI over CTor PET (19). At 
our institution, MRI is the imaging modality of 
choice due to its ease of acquisition and because 
we use it as standard modality in our algoritham 
of preoperative evaluation and clinical staging of 
patients with rectal and recently with colon cancer 
as well. We found MRI especially useful and bet-
ter than CT in distinguishing metastases from be-
nign entities such as cysts, adenomas, and heman-
giomas.
Laparoscopy
Even we do not use laparoscopy as diagnos-
tic tool at our institution, laparoscopy has emerged 
in recent years as a new diagnostic modality for 
patients with liver malignancies. The main advan-
tage of laparoscopy is fact that unnecessary lapa-
rotomys can be avoided in 78% of patients with 
unresectable disease (20). In selected cases, lapa-
roscopy can remarkably decrease the morbidity of 
surgery, and shorten the delay to systemic thera-
py. Laparoscopy is indicated in highly selected 
cases in which the results of imaging studies are 
suspicious and/or equivocal for extrahepatic tu-
mor, such as enlarged lymph nodes or possible 
peritoneal dissemination.
Preoperative biopsy
Percutaneous needle biopsies and fine needle 
aspiration (FNA) cytology are well established ap-
proaches for diagnosis, although, both unneces-
sary when imaging identifies new lesions with 
characteristic imaging features for CLM in pa-
tients with well known history. Needle biopsy 
may be appropriate when a benign or non-CLM 
lesion is suspected and can’t be differentiated non-
invasively with MRI/PET/CT and if would 
change the treatment plan eventually. Also, there 
is a potential for false negative results. Therewith, 
some authors reported that the benefit of this tool 
may be outweighed by the serious risk of needle 
tract seeding (21). For these reasons, needle biop-
sies and FNA cytology have been virtually aban-
doned in the preoperative evaluation of colorectal 
liver metastases. At our institution, we used nee-
dle biopsies for suspected non-CLM lesions on 
MRI forseveral patients with unknown primary 
cancer without any adverse outcomes.
SURGICAL TREATMENT
Definition of resectability and patient selection
The cornerstone of surgical treatment for 
CLM is proper patient selection. Patients with 
colorectal liver disease can be categorized into one 
of three major subtypes: clearly resectable, poten-
tially resectable, or definitely unresectable. Liver 
metastases numbering more than three, an inade-
quate resection margin of < 1 cm, the presence of 
extrahepatic disease, or involvement of hepatic 
pedicle lymph nodes used to be relative or abso-
lute contraindications for CLM liver resection. Ac-
cording to this definition, as few as 20% of CLM 
patients were resectable (7,22). However, these 
criteria have changed in recent years. Malik et al 
(23) reported that significant number of patients 
with multiple metastases (>4) survive to 5 years or 
more and should not be denied surgery (patients 
with 4-7 lesions and >7 had 35% and 24% 5-year 
OS, respectively). Previously widely accepted re-
section margin of at least a 1-cm has been aban-
doned because several studies have indicated that 
the actual resection margin did not affect OS as 
long as R0 resection could be accomplished(6,24). 
In the era of modern perioperative chemotherapy, 
even R1 (microscopically positive margin) resec-
tions could benefit in selected patients who are 
good responders to therapy (25). Equally, the pres-
ence of extrahepatic disease is also no longer con-
sidered an absolute contraindication for hepatic 
resection. Some authors have reported that the 
5-year OS after combined resection of lung and 
liver metastases is approximately 30% (26). In 
summary, resectability can be defined as ability to 
surgically remove all CLM with R0 (microscopi-
cally negative) margins while adequate future 
liver remnant (FLR) volume. Adequate FLR must 
have regenerative capacity and consist of at least 
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two liver segments with independent inflow/out-
flow and biliary drainage. The requirement for re-
sidual liver volume can be different for patients 
receiving chemotherapy. Although at least 20% of 
total liver volume should be preserved for a 
healthy liver, it is recommended that at least 30%-
40% should be preserved for livers damaged by 
chemotherapy-associated steatosis or hepatitis 
(27,28).
Regarding the patients selection, many pre-
dictive models have been created based on retro-
spective review of large series data. Fong et al. (7) 
had reviewed results of 1,001 patients undergoing 
liver resection for CLM over a 13-year period. 
Multivariate analysis identified several factors as-
sociated with poor overall survival including: 
positive margin, number and size of tumors, high 
pre-operative CEA, lymph node positive primary, 
and disease-free interval from the primary to dis-
covery of the liver metastases of < 12 months . 
Each clinical factor was assigned one point, and 
the total clinical risk score (CRS) was compared 
with the clinical outcome of each patient after liver 
resection. The total score was found to be highly 
predictive of long-term outcome (p<0.0001). The 
5-year actuarial survival rate for patients with 0 
points was 60%, whereas that for patients with 5 
points was 14%.A similar scoring system was pro-
posed by Nordlinger et al. (29) using data from 
1,600 patients in Europe. We have to emphasize 
that while these scoring systems are able to stratify 
patients into high and low risk groups, they do 
not surely identify patients in whom cure is ruled 
out.
Some technical aspects of liver resection
Initially, liver resection was based on the an-
atomic system described in the early 1950s by 
Couinaud (30), who defined the intrahepatic divi-
sions of blood vessels and bile ducts. Neverthe-
less, there was significant confusion regarding the 
description of liver anatomy and hepatic resec-
tions until the first universally accepted terminol-
ogy system was introduced. The “Brisbane 2000 
terminology of liver anatomy and resections” (31) 
was based on the internal anatomy and described 
the several levels of division of the liver segments. 
It is nowdays widely accepted among liver spe-
cialists.
The main purpose of liver resection is to re-
sect the tumor with a sufficient tumor-free mar-
gin, while preserving as much normal parenchy-
ma as possible. Previously, hepatic resections have 
been along the liver segmental anatomy planes 
and liver surgeons relied more on major resections 
( hemi-hepatectomies and trisectionectomies) be-
cause former data suggesting a higher positive 
margin rate with more limited, nonanatomical re-
sections (32). The nonanatomical or wedge resec-
tion, by removing a smaller volume of liver is as-
sociated with reduced postoperative morbidity 
and mortality. Although, they carry a higher risk 
of positive resection margins, in a recent series 
wherewedge resections were performed, the inci-
dence of positive resection margins was equiva-
lent for both wedge resection and segmental, ana-
tomical resection (8.3%), and the five-year survival 
was equivalent in both groups (33).
As we mentioned before, intraoperative ul-
trasound (IOUS) is very important tool in modern 
liver surgery. It can delineate the interior anatomy 
of the liver, including intrahepatic vessels, and al-
lows hepatic resection to be performed more safe-
ly and anatomically. Besides detecting additional 
intrahepatic nodules, IOUS is helpful in identify-
ing extrahepatic sites of the disease, such as infil-
trated lymph nodes in the celiac axis and the he-
patic pedicle, or deposits in the peritoneal cavity 
(34). Please note that it is very important that liver 
surgeons is well skilled in intraoperative hepatic 
ultrasonography.
Blood loss is among the most important fac-
tors influencing postoperative outcome from he-
patic resectio. Control of the hepatic inflow at the 
hilum should be achieved in all liver resections so 
that a vascular occlusion can be performed if nec-
essary. The variety of vascular occlusion tech-
niques ranges from Pringle’s maneuver (i.e. portal 
triad clamping) to total hepatic vascular exclusion, 
including inflow occlusion (selective or total), 
hemi-hepatic clamping, and ischemic pre-condi-
tioning. These methods can also vary with regards 
to timing and frequency (intermittent vs. continu-
ous) with all their advantages and disadvantag-
es(35). Additional tool in decreasing blood loss, 
postoperative morbidity and mortality is main-
taining low central venous pressure (CVP) during 
hepatic resection. A study by Melendez at al. (36) 
showed a dramatic decrease in operative blood 
loss, morbidity, and mortality when liver resec-
tion is performed under low CVP conditions. Im-
portantly, this study did not reveal any increase in 
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postoperative renal insufficiency and also empha-
sizes the importance of good collaboration be-
tween the anesthesiologist and the surgeon as key 
point in minimizing blood loss during resection.
There is a variety of techniques and devices 
used for parenchymal transection, including the 
clamp crushing technique, Cavitron Ultrasonic 
Surgical Aspirator (CUSA, Covidien, Mansfield, 
MA, United States), Hydrojet (Hydro-Jet, Erbe, 
Tubingen, Germany), The Harmonic Scalpel (Eth-
icon Endo-Surgery, Cincinnati, OH, USA) and bi-
polar sealing devices. The goal of all techniques is 
to quickly and safely divide the parenchyma while 
minimizing damage to inflow and outflow struc-
tures from the parenchyma to be left behind. Tran-
section of the liver should be performed as a care-
ful dissection with division of relevant vascular 
structures rather than blind coagulation. Among 
these, the clamp crushing technique remains the 
most efficient in terms of reduced operation time, 
blood loss and total costs (37). Also, appliance of 
each technique is in the domain of surgeon and 
institutional preferences. Aragon at al. (38) dis-
cussed the most widely (above mentioned) used 
methodes at present and review the existing ran-
domized data comparing them. They concluded 
that the use of one tool over the other will also 
vary according to the type of resection, and differ-
ent techniques can be more advantageous in one 
setting than another. It is important to be familiar 
with many strategies and be able to apply them in 
the most appropriate setting.
How the role of laparoscopy in surgery is a 
growing field, it is now brought into liver resec-
tions in institutions experienced with minimally 
invasive surgical techniques. The majority of cases 
have been done total laparoscopic followed by 
hand assisted laparoscopic. The most common 
liver resections performed laparoscopically are 
wedge resections, followed by left lateral segmen-
tectomy (39). Generally, tumors in the periphery 
of the liver are also considered amenable to resec-
tion. Major hepatectomies, whether left or right, 
are not as commonly performed.The technique in-
volves using ultrasonic shears to dissect paren-
chyma with placement of clips on vessels or use of 
endo-GIA staplers for ligation of vasculature. In 
2008 a consensus meeting at the University of 
Louisville established guidelines for minimally 
invasive liver surgery (39). Data currently shows 
the benefit of minimally invasive technique to be 
decreased blood loss, shorter hospital stay, and 
decrease use of pain medication. From oncological 
ascpet, there should not be any concerns because 
reported negative margin is 94.4%, with overall 
survival of 50% at 5 years (39). In experienced cen-
ters, there does not appear to be any difference in 
DFS or OS between open versus laparoscopic liver 
surgery. However, the open surgical approach to 
liver resection will continue to grow and develop 
with technology. With growing interest in mini-
mally invasive approach to liver resection, this 
adds an additional tool to the technology avail-
able for open surgery which will always be the 
gold standard.
At our institution, we routinely perform 
IOUS after liver mobilisation. For control of he-
patic inflow we perform Pringle’s maneuver, 
whether in intermittent or continuous manner, 
depending on extent of liver tissue to be resected. 
For parenchymal transection we mostly use com-
bination of crash/clamp technique, ultrasonic dis-
section and stapling devices.We use ultrasonic 
dissector as crash and clamp tool to first distin-
guish blood and bile structures and then ligate it 
(vibrating ultrasonic shears seal and divide blood 
vessels from 3 mm to 7 mm in diameter). We 
routinly use vascular stapling devices in major 
hepatectomies as they have become an accepted 
method of liver transection. Initially used primar-
ily for division of major vessels, their use has been 
expanded to divide hepatic parenchyma. Staplers 
have the potential to be serially applied and fired 
in quick and efficient manner, thus decreasing 
overall operating time. As sort of validation for 
their use we found study by Reddy et al. (40).who 
published a retrospective series of 200 patients 
over 10 years who underwent partial hepatectomy 
with either the crush-clamp alone or vascular sta-
pler techniques. Compared to crush-clamp, use of 
a vascular stapler was associated with less opera-
tive time, blood loss, and transfusion require-
ments.
Surgical treatment for clearly resectable 
colorectal liver metastases
Treatment of resectable synchronous CLM
Synchronous hepatic metastases occur in up 
to 25% of newly diagnosed CRC (41), and they 
present a challenging problem for the multidisci-
plinary team. The natural history of CLM suggests 
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that resection of an asymptomatic primary tumor 
without liver resection with curative intent offers 
poor long-term benefit (<5% 5-year OS) (42). The 
optimal timing of primary tumor and hepatic me-
tastases resection in synchronous resectable CLM 
patients is somehow still controversial. Treatment 
sequencing can be simplified into the following 
three paradigms: classic (colorectal-first; staged), 
simultaneous (combined), or reverse approach 
(liver-first) .The decision of whether to treat the 
CLM or CRC first depends on which site domi-
nates both oncologically and symptomatically, 
which requires multidisciplinary discussions with 
liver surgeon playing a central role. Unilateral de-
cision-making, often by thephysician who first en-
counters the patient, can potentially limit a pa-
tient’s curative options. In the past, these patients 
were managed by classic, staged approach (i.e., 
liver resection following primary tumor resection 
and optional chemotherapy) based on observation 
that simultaneous resection of primary tumour 
and CLM is associated with increased morbiditiy 
and mortality (29,43,44). Simultaneous resection 
has been increasingly adopted in recent years due 
to novel reports that perioperative morbidity and 
mortality of simultaneous resection are compara-
ble to those of staged resections (41,45). No sig-
nificant difference in 5-year survival was found 
between these two groups in a systemic analysis. 
Actually, no real indications or contraindications 
exist for simultaneous resection of hepatic metas-
tases. For patients needing minor hepatectomy, 
the extent of primary tumour resection prevails 
decision-making. For low-risk CRC resections, in-
cluding low anterior resections, a simultaneous 
approach can be performed safely with minor 
hepatectomy, potentially decreasing length of 
stay, cost, and patient disability (46–48). For more 
extensive CRC resections, the classic (staged) ap-
proach is more suitable and safer. When indicated, 
patients with rectal cancer receive preoperative 
chemoradiation prior to resection. Additionally, 
simultaneous resection offers the advantage of 
completing the local control of the disease in a 
single procedure, allowing the use of adjuvant 
chemotherapy for systemic micrometastases (45). 
Still, Reddy et al. (48) have reported that patients 
undergoing simultaneous major hepatectomy (i.
e., resection of three or more liver segments) had a 
significantly higher mortality (8.3% vs 1.4%) and 
severe morbidity (36.1% vs 17.6%) than those re-
ceiving staged resection.
Staged resectionis recommended for the fol-
lowing cases: significant comorbidities precluding 
longer operative time for simultaneous resection, 
marginal/inadequate FLR, and/ or complex op-
erations needed at both sites such as major hepa-
tectomy plus total colectomy with/ or proctecto-
my. When there is symptomatic CRC (bleeding or 
obstruction), priority in sequencing goes to pri-
mary.
A new modality has been proposed more re-
cently, called the “liver-first” or reverse strategy, 
and involves first, liver resection, with or without 
preoperative chemotherapy, followed by optional 
chemotherapy after hepatectomy, and finally, pri-
mary tumour resection. This approach may be 
suitable for borderline resectable liver metastases, 
which may lose the precious time frame of surgi-
cal treatment if delayed and forpatients with as-
ymptomatic primary tumors and CLM requiring 
major hepatectomy. For properly selected pa-
tients, reverse approach is oncologically safe with 
good OS (49,50). The positive effect of this strategy 
is the fact that treating the liver first offers the abil-
ity to control metastatic disease early before po-
tential progression beyond resectability (51). Once 
the metastatic disease is resected, locoregional 
control is the next priority. As well, if the patient’s 
disease systemically progresses after hepatecto-
my, then the patient is spared an unnecessary CRC 
procedure and potential ostomy.A potential dis-
advantage of this approach is that the primary tu-
mour may progress and require emergency sur-
gery during this process. Maybe that is why deci-
sion-making analysis has indicated that it is least 
probable to complete all planed sequential treat-
ment for the liver-first approach among the above 
mentioned three treatment strategies. Thankfully, 
primary tumour progression during chemothera-
py rarely (5–7 %) demands a strategy change 
(49,52).
Treatment of resectable metachronous CLM
At present, complete surgical resection is the 
primary therapy for patients with resectable meta-
chronous CLM. Although the most fascinating 
benefit of preoperative chemotherapy is the con-
version of unresectability to resectability, for ini-
tially resectable CLM patients periopertive che-
motherapy is often used, but it still draws contro-
versy among liver suregons. The most serious 
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concern about preoperative (neoadjuvant) chemo-
therapy is whether it can bring about a survival 
benefit for these patients. Multiple studies on the 
treatment of primary CRC have encouraged dis-
cussions, if perioperative chemotherapy improves 
survival after resection of CRC liver metastases. 
The most relevant and the only published ran-
domized prospective clinical trial to investigate 
the role of neoadjuvant chemotherapy in CLM pa-
tients, EORTC 40983 (53), indicated that patients 
with initially resectable CLM undergoing liver re-
section plus six cycles of preoperative FOLFOX4 
and six cycles of postoperative FOLFOX4 chemo-
therapy had a better 3-year progression-free sur-
vival (PFS) compared to those receiving liver re-
section alone.There were more reversible postop-
erative complications in the chemotherapy patients 
(25 vs. 16 %, p0.04), but no increase in mortality 
(1 % in each arm). Noteworthy, there was a sig-
nificant defect in this study: patients in the control 
group did not undergo chemotherapy after hepat-
ic resection. So, it is difficult to determine whether 
the reported PFS improvement is brought about 
by preoperative chemotherapy, postoperative 
chemotherapy or both.
Further, we have to emphasize a several po-
tential drawbacks of neoadjuvant chemotherapy 
in resectable CLM patients. First is possible miss-
ing the optimal timing of liver resection because 
of complete response of liver metastases during 
neoadjuvant chemotherapy. Approximately 4% of 
patients achieved a radiographic complete re-
sponse (CR) to chemotherapy, and 9% had a path-
ological CR (54,55). Radiographic CR mostly does-
not mean true liver metastases remission. Viable 
cancer cells can be pathologically found in 80% of 
patients with a radiographic CR and undergoing 
resection according to the prior sites (56). Approx-
imately 60 % of “disappeared metastases” will re-
cur if are kept in place without resection (57). 
However, from surgical point of view, it is not al-
ways easy to perform hepatic resection according 
to the previous site of disappearing liver metasta-
ses. To avoid such scenario, it is recommended 
that the evaluation of liver lesions should be re-
peated every 2 months during preoperative che-
motherapy (58,59).
Afterward, a second potential drawback of 
neoadjuvant chemotherapy is progression of dis-
ease. In those patients, tumour progression can 
compromise their opportunity for resection and 
potentially good outcome.The previously men-
tioned EORTC 40983 clinical study (53), reported 
that 7% of initially resectable CLM patients had 
progressive disease (PD) during neoadjuvant che-
motherapy, and 4% did not complete liver resec-
tion whether to prior liver disease progression or 
the presence of newly detected extrahepatic dis-
ease. After all, another issue concerning PD is 
whether they should be resected even if it is fea-
sible. Adam et al. (60) have advocated that liver 
PD during chemotherapy indicates poor progno-
sis after resection and should be considered as a 
contraindication to liver resection. They reported 
a dismal 5-year OS (8%) and DFS (3%) after liver 
resection in patients with tumour progression 
during neoadjuvant chemotherapy. However, 
other studies have indicated that the response to 
neoadjuvant chemotherapy has no prognostic val-
ue (61,62).
At last, chemotherapy-associated liver injury 
(CALI) is important drawback related to neoadju-
vant sistemic therapy.The majority of CLM pa-
tients are treated with chemotherapy prior to liver 
resection. Current most applied protocols are 
FOLFOX and FOLFIRI with addition of new bio-
logical agenst such as Bevacizumab, Cetuximab 
and Panitumumab. Because of their efficacy, phy-
sicians have used above mentioned regimens to 
increase cure rates in resectable CLM, downsize 
borderline resectable cases, and attempt to convert 
unresectability to resectability. Consequently, that 
has led to extended systemic treatment before sur-
gical referral. However, extended duration (>8 
cycles) chemotherapy only increases the risk of 
CALI without improving pathologic response be-
cause the type of chemotherapy has more impact 
on pathologic response rather than the duration of 
chemotherapy (63). Thereby, assumption that all-
patients with CLM should be seen by a liver sur-
geon who is in charge of multidiscplinary team 
before chemotherapy, is gaining in importance. 
The goal of such multidisciplinary strategy is re-
ducingchemotherapy to the point of resectability 
and thus avoiding overtreatment having on mind 
that further chemotherapy can be given postoper-
atively.
There are two types of CALI: non-alcoholic 
fatty liver disease (i.e., steatosis/steatohepatitis) 
and vascular sinusoidal obstruction. All three 
commonly used chemotherapeutic agents for 
CRC, 5-FU, oxaliplatin and irinotecan, can induce 
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steatosis with an incidence rate of 30%-40%. Ap-
proximately 3.6%-8% (59,64) of patients have che-
motherapy induced steatohepatitis, which is rela-
tively more common in patients receiving irinote-
can as compared with those receiving 5-FU. On 
the other hand, irinotecan has been associated 
with both steatosis and steatohepatitis, especially 
in patients with clinical symptoms of metabolic 
syndrome (obesity and diabetes) (65). Macroscop-
ically, the result is “yellow liver”. Irinotecan’s in-
duced steatohepatitis is the only CALI associated 
with increased mortality from postoperative he-
patic insufficiency (66). This is most important 
when choosing between FOLFOX and FOLFIRI. 
Oxaliplatin is associated with a spectrum of vas-
cular injuries, macroscopically presenting as a fri-
able “blue liver“. This type of hepatotoxicity has 
been associated with increased perioperative 
transfusions but not mortality (67).
Surgical treatment for unresectable CLM 
with potential convertibility
As we mentioned above, majority of CLM 
patients are initially unresectable (extensive and 
bilobar disease) but have the potential to become 
resectable through conversion therapeutic strate-
gies including chemotherapy, embolization, two-
staged operation or the combination of ablation 
therapy. The ability to treat patients with such ex-
tensive CLM depends on institutional resources 
(i.e., multidisciplinary teams and interventional 
radiology) besides well trained and experienced 
liver surgeons.
Conversion chemotherapy (“downsizing“ of CLM)
When patients present with anatomically un-
resectable CLM ( approximately 80%-90% of CLM 
patients at diagnosis), the first consideration 
should be the ability to downsize their lesions to 
resectability. Thanks to the development of new 
chemotherapy agents and targeted biological 
agents, chemotherapy can convert a considerable 
portion of initially unresectable CLM into resect-
able disease, which is called conversion chemo-
therapy (59,68,69). Effective chemotherapy may 
achieve this goal in 10–20 % of initially unresect-
able patients, and these patients who achieve re-
sectability share long-term survival rates that are 
far superior to palliative chemotherapy and ap-
proach that of patients with initially resectable 
CLM (11,70). First, Bismuth et al. (68). in 1996 re-
ported that preoperative chemotherapy, using ox-
aliplatin plus 5-FU/LV, enabled 16% (53/330) of 
initially unresectable CRLM patients to gain the 
chance of undergoing liver resection with a 5-year 
OS of 40%. In 2001, Adam et al. (58) reported that 
13.6% (95/701) of initially unresectable CLM pa-
tients underwent hepatic resection after systemic 
neoadj. chemotherapy and achieved a 5-year OS 
of 34%. In one italian study, Nuzzo at al. (71) re-
ported that in about one-third of the patients with 
primarily unresectable CLM, downsizing of the 
lesions by chemotherapy (FOLFIRI protocol) per-
mitted a subsequent curative resection. In recent 
years, the addition of targeted agents such as be-
vacizumab and cetuximab to chemotherapy has 
been shown to further improve the conversion 
rates. The monoclonal antibody, bevacizumab, 
targeting vascular endothelial growth factor 
(VEGF), has shown promising results in the treat-
ment of CLM. In a first-line setting, overall re-
sponses were between 45% and 70% when com-
bined to 5-FU, LV and irinotecan (72,73). Present 
data suggests that liver resection should be per-
formed at least 6-8 weeks after administration of 
the last dose of bevacizumab, because bevacizum-
ab can cause bleeding, delayed wound healing, 
and bowel perforation (74,75). Cetuximab, on the 
other hand, is the anti-EGFR agent tailored for use 
in patients whose tumors express wild-type 
KRASmutation. In the CELIM study (76), 106 pa-
tients with initially unresectable CLM underwent 
cetuximab plus FOLFOX6 or cetuximab plus FOL-
FIRI and achieved an objective response rate of 
68% and 57%, a liver resection rate of 40% and 
38%, and a R0 liver resection rate of 38% and 30%, 
respectively.
Neoadjuvant conversional chemotherapy can 
also be used via hepatic arterial infusion (HAI) 
with high response rates, as first or second-line 
therapies. The ideal candidates are patients with 
lesions confined to the liver, without severe asci-
tes or jaundice (77). Data from several clinical tri-
als with oxaliplatin or irinotecan via HAI have 
been promising (78). However, HAI has several 
disadvantages such as limited expertise, high cost 
of infusion pumps and considerable morbidity 
due to catheter-related complications, particularly 
sclerosing cholangitis. Therewith, HAI is rarely 
used outside specialized treatment centers (79).
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In summary, conversion therapy has showed 
acceptable results despite potential drawbacks 
mentioned in chapter before, but still there are fe-
wrather unanswered questions: which protocol 
should be applied; how many cycles before surgi-
cal intervention and finally, when we should start 
palliative tretament ?
Portal vein embolization (PVE)
Portal vein embolization (PVE) is another mo-
dality commonly used preoperatively for patients 
where the extent of liver resection is expected to 
result in less than the optimal functional liver vol-
ume of 20% to 40%, necessary to prevent postop-
erative liver failure (80). (PVE) can be helpful to 
induce ipsilateral atrophy and contralateral hy-
pertrophy to fulfill the minimal liver volume re-
quirement (10) and by that to expand the number 
of patients undergoing curative hepatectomy for 
CLM. PVE can be performed by a percutaneous 
transhepatic approach as well as by a transileoco-
lic approach during laparotomy (81). The percuta-
neous method consists of accessing the portal vein 
via a transhepatic route under sonographic and 
fluoroscopic guidance (81). Venous portography 
then allows selective catheterization and emboli-
zation of one of the portal branches. The most 
commonly used agents for embolization include 
gelatin sponge particles (Gelfoam) with iodized 
oil (Lipiodol), cyanoacrylate, alcohol, fibrin glue, 
or gelatin sponge, but none of them emerged as 
superior to the others (10,82). After PVE, hepatic 
vol-ume is routinely evaluated using computed 
tomography volumetric analysis. This imaging 
modality enables the surgeon to determine the de-
gree of compensatory hypertrophy of the future 
remnant liver as well as to reevaluate metastatic 
disease. Generally, 4-6 weeks after embolization 
adequate hypertrophy has occurred to enable safe 
hepatic resection(10). Azoulay at al. (82) have re-
ported on a group of 30 patients who were deemed 
unresectable because the estimated FLR was con-
sidered too small. These patients underwent PVE 
with minimal morbidity and no mortality. PVE 
substantially increased the FLR, providing liver 
resection feasible in 19 patients (63%), with low 
morbidity and mortality rates and survival rates 
similar to the patients who did not undergo PVE. 
As PVE is more used as treatment modality some 
disadvantages have emerged. Thrombosis, and/
or migration of the emboli to the contralateral he-
patic lobe, hemoperitoneum, hemobilia, and tran-
sient liver insufficiency, are complications occur-
ring in 10% of cases and can be easily managed(80). 
Another potential drawback is the possibility that 
PVE may stimulate the growth of tumours in the 
contralateral liver lobe, although this has yet to be 
clarified. A way of counteracting this effect is the 
administration of concurrent chemotherapy 2-3 
weeks after PVE, thus preventing interference 
with initial liver regeneration (83).
Two-staged hepatectomy
A two-stage procedure is indicated in some 
patients cannot become eligible for complete CLM 
resection through a single hepatectomy even after 
preoperative chemotherapy or PVE. These pa-
tients usually have multinodular, large metastases 
involving both liver lobes, which cannot be re-
moved in a single hepatectomy owing to a too 
small volume of the FRL. The two-stage procedure 
consists of two subsequent hepatectomies, and 
takes advantage of physiological liver regenera-
tion to accomplish radicality. The objective of the 
first hepatectomy is to make the second hepatec-
tomy potentially curative (83). At the first hepa-
tectomy, as much as possible of liver metastases is 
resected from the less-invaded hepatic lobe. After 
regeneration of the FLR, the remaining tumoral 
tissue in the opposite lobe is resected during a sec-
ond operation. To control tumor growth between 
the two hepatectomies, chemotherapy is applied, 
generally starting 2-3 weeks after the first hepatec-
tomy to prevent interference with liver regenera-
tion. If the estimated FLR volume after the second 
hepatectomy is below 30% (40% for liver heavily 
treated with chemotherapy), PVE can be per-
formed as additional procedure during the first 
operation.
In 2000, Adam et al. (83) first proposed the 
two-stage resection strategy when they reported 
the initial results from 13 patients undergoing 
two-stage hepatectomy with a 3-year survival rate 
of 35%. No perioperative deaths occurred at the 
first hepatectomy, compared to a perioperative 
mortality of 15% at the second hepatectomy. Mor-
bidity rates were higher after the second hepatec-
tomy compared to the first operation (45% versus 
31%, respectively). An updated result of a 5-year 
OS of 42% in 41 patients receiving two-staged re-
51
Libri Oncol., Vol. 41 (2013), No 1–3, 41 – 58
section was reported in 2008 (84). This approach 
can also be used at the time of colectomy when 
multiple synchronous hepatic lesions preclude a 
single curative hepatectomy. In such cases, a lim-
ited resection of the metastatic load of one hemili-
ver could be done at the same time as resection of 
primary tumour, leaving the second major hepa-
tectomy to be done in a second stage (85). For 
highly selected patients with multiple, bilobar 
colorectal liver metastases, a two-stage hepatecto-
my can offer long-term remission.
A novel method for extensive growth of FLR, 
as an efficient alternative to PVE, have been re-
cently proposed. “ALPPS” stands for Associating 
Liver Partition with Portal Vein Ligation for 
Staged Hepatectomy (ALPPS). ALPPS is the most 
recent modification of the techniques developed 
for two-stage hepatectomies that allow resection 
of advanced CLM in two steps by making use of 
the regenerative capacity of the human liver. 
ALPPS was first described by Regensburg’s group 
from Germany (86). ALPPS allows to remove an 
extensive part of the liver in two steps. In the first 
step the liver parenchyma is transected along the 
intended line of resection and the future liver re-
mant cleaned by partial resections from all tumor 
tissue in the case of bilobar tumors. To this a por-
tal ligation of the larger liver lobe that will have to 
be removed is added. The patient is then allowed 
to recover. After a waiting period of 1-2 weeks the 
second step is performed in which the deportal-
ized liver is removed to make the pateint com-
pletely tumour-free.The new strategy offers two 
adavantages: first, it elegantly addresses the most 
feared complication following major hepatecto-
mies, i.e. postoperative hepatic insufficiency. The 
dieseased right hemiliver, left in place, acts as an 
auxiliary livere to assist the future liver remnant 
for the first and critical week after resection. Sec-
ond this new operation induces an amount of hy-
pertrophy that is unparalleled by other techniques. 
Schnitzbauer et al. (86) report a 74% volume in-
crease of the remnant liver in a mean of 9 days. 
Although very promising, some considerations 
about this method have to be made. First ofall, the 
technique has not yet been standardized. We 
should consider that the method has not yet been 
tested in an evidence based manner, only prelimi-
nary experience is available, very little data exist 
and mortality rates in initial reports are concern-
ing (86,87).
Ablation therapy
Locally ablative modalities, such as radiofre-
quency ablation (RFA), cryotherapy or laser-in-
duced interstitial thermo-therapy (LITT) can be 
added to hepatic resection, to offer curative treat-
ment in patients with unresectable tumors. The 
goal of the combined approach is to resect the ma-
jority of metastases and to ablate the residual 
smaller lesions, to achieve a R0 status, preserving 
at the same time adequate FLR volume to avoid 
PHI (88). RFA is the most widely used moality. 
RFA is based upon the deliverance of a high-fre-
quency (460e500 kHz) alternating current through 
a probe positioned in the tumour, which is turned 
into heat (>50°C) that causes tissue hyperthermia 
and cellular destruction (89). Although appealing 
as a less invasive treatment option, RFA is associ-
ated with higher local recurrence rates, especially 
for tumors >3 cm, multiple tumors, and tumors 
close to major vessels due to the heat sink effect. 
RFA plays a role in surgical therapy for highly se-
lected patients with small tumors located away 
from major abdominal, biliary, and vascular struc-
tures but should be considered inferior to resec-
tion in terms of local control for CLM. However, 
RFA is inferior for local control of metastatic le-
sions, systemic spread, and long-term survival. 
There is a higher local recurrence rate associated 
with RFA than with resection, resulting in inferior 
disease-free survival rate (90). Therefore, for the 
treatment of solitary hepatic metastases, the appli-
cation of RFA cannot be primarily recommended. 
On the other hand, RFA can be used as palliative 
treatment for unresectable metastases, as it 
achieves better survival than chemotherapy (90). 
There are three approaches for RFA, including 
percutaneous, open and laparoscopic. Ablation 
through the open approach seems to be superior 
to the percutaneous or laparoscopic methods in 
terms of local failure rate. Reported local recur-
rence rate is up to 43% (91).
Treatment for clearly unresectable CLM
Synchronous unresectable CLM – need of primary 
tumour resection
Generally, palliative primary tumour resec-
tion is required and advocated for patients with 
definitely unresectable metastatic colorectal can-
cer who have symptoms related to intestinal ob-
struction, perforation or intractable bleeding. Ne-
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vertheless, for asymptomatic patients with unre-
sectable CLM, the value of primary tumour 
resection is still questionable. In earlier studies, 
authors have suggested that primary tumour re-
section may have potential benefits in preventing 
tumor-related symptoms such as obstruction, 
which may require emergency operations with a 
high risk of surgical mortality (92). Nowdays, 
those claims are rather questionable with the ap-
plication of novel chemotherapy agents that have 
ability to control intestinal symptoms. Thus, US 
National Comprehensive Cancer Network guide-
lines recommend that colon resection should be 
considered only for impending obstruction risk or 
intractable bleeding. Temple et al. (93) in study 
based on 9000 elderly CLM patients reported that 
72% of them underwent resection of the primary 
tumour and 20% of them had symptoms of bowel 
obstruction, perforation or bleeding. It suggests 
that a majority of incurable CRC patients receive 
intestinal resection without a clear and reasonable 
indication. On the other hand, the study from Me-
morial Sloan-Kettering Cancer Center reported 
233 metastatic CRC patients receiving chemother-
apy without the primary tumour resection. Only 
7% of the patients required palliative primary tu-
mour resection during the disease course. Thus, 
the authors recommended chemotherapy without 
prophylactic primary tumour resection as a stan-
dard management of metastatic colorectal cancer 
without obstruction or bleeding symptom (52).
Novel therapeutic agents in combination 
with chemotherapy
Several randomized clinical trials has vali-
dated the survival benefit of adding targeted ther-
apeutic agents such as bevacizumab, cetuximab 
and panitumumab to traditional chemotherapy in 
patients with clearly unresectable CLM. The BEAT 
study (94) indicated that bevacizumab-based com-
bination chemotherapy is efficient in metastatic 
colorectal cancer. It included 1965 CLM patients 
undergoing bevacizumab combined with differ-
ent types of chemotherapy as the first-line thera-
py, and demonstrated that the PFS in patients re-
ceiving bevacizumab plus FOLFIRI, FOLOFOX or 
Xelox was > 10 mo and the OS approached or ex-
ceeded 24 mo. The CRYSTAL study (95), which 
compared cetuximab plus FOLFIRI with FOLFIRI 
alone in the initial treatment of CLM patients, in-
dicated that cetuximab improved the response 
rate (57.3% vs 39.7%, P < 0.0001), PFS (9.9 mo vs 
8.4 mo, P = 0.0012) and OS (23.5 mo vs 20.0 mo, 
P = 0.0094) significantly in patients with wild-type 
KRAS. However, in a population subset with mu-
tant KRAS, there was no significant difference in 
the response rate, PFS or OS between the two 
groups. In a phase III clinical trial(96), 463 CLM 
patients received either pani- tumumab plus best 
supportive care (BSC) or BSC alone after chemo-
therapy failure. Patients with panitumumab plus 
BSC had an objective response rate of 8% and a 
sig-nificantly better median PFS (96 d vs 60 d) than 
those who received BSC alone. In summary, from 
these trials we may conclude that targeted thera-
py, in addition to traditional chemotherapy, im-
proves the survival of unresectable CLM patients. 
However, an important issue is how to accurately 
predict the tumor response to targeted therapy, 
and that should be further investigated, in consid-
eration of its high cost.
Repeated resections
The majority of patients with CLM (55%-
60%) will develop recurrent disease in the liver 
within the first two years after surgery, despite 
any mode of treatment that they have received 
(97). Therefore, a repeat resection would be the 
onlychance to prolong life for these patients. In 
most cases, repeated resecion is combined with a 
locally ablative therapy, mainly with RFA. The re-
sults of repeat curative resection are comparable 
to the first one. The only drawback with a second 
or third hepatectomy on the same patient is in-
creased technical difficulty. Repeat resection car-
ries perioperative morbidity and mortality rates of 
5%-7% and 20%-39%, respectively (9). Thus, re-
peat hepaticresection provides similar long-term 
survival to primary hepatectomy, without increas-
ing perioperative morbidity and mortality (98). 
Indeed, Pessaux et al. (99) indicated that overall 
five-year survival rates after the first, second and 
third hepatectomy are similar: 33%, 21% and 36%, 
respectively. Adam et al. (100,101) in their studies 
pointed out several prognostic factors determin-
ing patient eligibility and probable success after a 
third hepatectomy. These factors are: the curative 
nature of the first two hepatectomies, an interval 
of more than one year between the two proce-
dures, the number of recurrent tumors, serum 
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CEA levels, and the presence of extrahepatic dis-
ease. In conlusion, the bestcandidates for repeat 
resection are patients with a low tumor load, no 
extrahepatic disease, and removal of all visible 
metastatic load during the second hepatectomy 
(102). However, the role of repeat liver resection 
in patients with intrahepatic recurrence still re-
mains controversial, because of the disputable 
survival benefit and the additional risks of repeat 
surgery.
Follow up after resection
Patients who have undergone hepatic resec-
tion of CLM are followed up to identify early re-
currence that may be amenable to repeat resection 
with curative intent. Most patients undergo serial 
physical examination, serum CEA level, chest 
X-ray, and CT/ MRI of the upper and lower abdo-
men every 3 to 4 mo for the first two years and 
then every 6 mo for the following five years.
ADJUVANT CHEMOTHERAPY
Adjuvant chemotherapy for stage III CRC 
cancer patients has been widely accepted based 
on solid evidence for survival benefit. Therefore, 
postoperative chemotherapy after CLM resection 
is also accepted by many oncologists and has be-
come common practice with main purposeof re-
ducing high risk of recurrence after surgery. Still, 
considerable controversy exists regarding the role 
of adjuvant chemotherapy following complete re-
section of CLM. There have been few prospective 
randomized clinical studies that have investigated 
the adjuvant chemotherapy survival benefit after 
liver resection, and the sample size of these stud-
ies has been limited due to difficult accrual. In first 
study, by Portier et al. (103), after resection of 
CLM, adjuvant 5-FU–LV resulted in a significant-
ly better 5-year DFS compared with the observa-
tion group (33.5% vs 26.7%, P = 0.028). There was 
also a trend toward better OS in the adjuvant che-
motherapy group, although this was not statisti-
cally significant (51.1% vs 41.1%, P = 0.13).This 
study was prematurely stopped due to slow ac-
crual. To improve the sample size and power, Mi-
try el al. (104) pooled results of this trial with a 
similar study (ENG (EORTC/NCIC CTG/GIVIO)). 
With a total of 278 patients in the combined analy-
sis, authors showed a 9- and 15-month impro-
vement in PFS and OS in multivariable analysis, 
respectively. Regardless the larger sample sizes, 
they were still unable to reach statistical signifi-
cance leaving considerable doubt about the effi-
cacy of adjuvant chemotherapy. Related to this 
subject, Rahbari et al. (105) in their recent study 
evaluated if patients’ clinical risk profile using the 
Memorial Sloan- Kettering Cancer Center clinical 
risk score (MSKCC-CRS) (7), which we mentioned 
before, may serve as a tool to predict the efficacy 
of adjuvant chemotherapy after resection of 
colorectal liver metastases. They concluded that 
adjuvant chemotherapy after potentially curative 
resection of CRC liver metastases is associated 
with favorable outcome in high-risk patients, but 
it offers no survival benefit in patients with low-
risk features of disease. The MSKCC- CRS might 
thus offer a tool to tailor adjuvant therapy after 
resection of CLM.
CONCLUSION
Multidisciplinary treatment has become the 
standard practice for CLM management. In recent 
years we have witnessed the improvement in the 
diagnostic cross-sectional imaging, new chemo-
therapeutic regimens and agents, and surgical 
techniques in the management of CLM. Still, R0 
liver resection has been recognized as the only 
treatment that could offer long-term survival. The 
cornerstone of surgical treatment for CLM is 
 proper patient selection. Previous eligibility crite-
ria for resection, indications, contraindications 
and risk factors have been abandoned. The pres-
ent viewpoint is that resection should be per-
formed if all metastases could be removed, while 
leaving a sufficient remaining liver parenchyma, 
regardless of their number, size, location and dis-
tribution (including extrahepatic disease as well). 
Nowdays, adequate use of novel chemotherapy, 
PVE and/or two-stage hepatectomy and locally 
ablative modalities, is able to improve the resect-
ability range and prognosis in these patients. Al-
though outcomes have improved, the risks of liver 
surgery such as bleeding and postoperative liver 
failure remain and these operations should be per-
formed in experienced, high volume centers with 
appropriate auxilliary support. Even though com-
monly used, perioperative chemotherapy contin-
ues to be controversial and while reasonable to 
consider, its efficacy is largely questionable in pa-
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tients with initially resectable disease. Preopera-
tive/ neoadjuvant chemotherapy is effective op-
tion for initially unresectable patients to be con-
verted into resectable. The role of adjuvant 
chemotherapy after CLM resection still needs to 
be clarified. Therefore, this paper emphasizes the 
significance of a multidisciplinary approach in the 
careful assessment of the risks, benefits, technical 
issues and oncological options for each individual 
case.
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